Positron emission tomography tracers in medullary thyroid carcinoma: Current evidence and emerging targets

doi:10.4329/wjr.v18.i5.120146

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 5

This Article

(21)

(18)

(0)

(36)

(456)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Radiology

ISSN

1949-8470

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Radiol. May 28, 2026; 18(5): 120146
Published online May 28, 2026. doi: 10.4329/wjr.v18.i5.120146

Full Size Figure Download Figure

Figure 2 Biology-guided imaging algorithm for positron emission tomography tracer selection in patients with biochemical recurrence of medullary thyroid carcinoma. The algorithm integrates calcitonin doubling time and clinical context to guide first-line tracer choice among ¹⁸F-fluorodihydroxyphenylalanine, ¹⁸F-fluorodeoxyglucose, and Gallium-68-labelled somatostatin receptor positron emission tomography/computed tomography. MTC: Medullary thyroid carcinoma; DT: Doubling time; Ctn: Calcitonin; CEA: Carcinoembryonic antigen; ¹⁸F-FDOPA: ¹⁸F-fluorodihydroxyphenylalanine; PET/CT: Positron emission tomography/computed tomography; ¹⁸F-FDG: ¹⁸F-fluorodeoxyglucose; ⁶⁸Ga-SSTR: Gallium-68-labelled somatostatin receptor; FDOPA: Fluorodihydroxyphenylalanine; SSTR: Somatostatin receptor; PRRT: Peptide receptor radionuclide therapy; TKIs: Tyrosine kinase inhibitors.

Citation: Ahmed FW, Ahmed F. Positron emission tomography tracers in medullary thyroid carcinoma: Current evidence and emerging targets. World J Radiol 2026; 18(5): 120146
URL: https://www.wjgnet.com/1949-8470/full/v18/i5/120146.htm
DOI: https://dx.doi.org/10.4329/wjr.v18.i5.120146

Ahmed FW, Ahmed F. Positron emission tomography tracers in medullary thyroid carcinoma: Current evidence and emerging targets. World J Radiol 2026; 18(5): 120146 [PMID: 42238228 DOI: 10.4329/wjr.v18.i5.120146]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.